Trial Profile
A Study to Evaluate the Efficacy of Anti-emetic Drug Aprepitant Upon the Combination Chemotherapy of Nedaplatin and Docetaxel for Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2020
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 28 Aug 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 ClinicalTrials.gov.
- 21 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.